Myokardia, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2012-09-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.myokardia.com
Clinical Trials
59
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT03470545
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Cedars-Sinai Medical Center (Smidt Heart Institute), Los Angeles, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03442764
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Cedars-Sinai Medical Center (Smidt Heart Institute), Los Angeles, California, United States
🇺🇸Stanford Hospital and Clinics/Stanford University, Palo Alto, California, United States
A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
- Conditions
- Dilated Cardiomyopathy
- Interventions
- Drug: MYK-491 or placebo
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03062956
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
- Conditions
- Left Ventricular Outflow Tract ObstructionCardiomyopathy, Hypertrophic Obstructive
- Interventions
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02842242
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02480296
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
- Prev
- 1
- 2
- Next